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Objective: To examine the efﬁcacy of 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-
methylpyridin-4-one (CM1) iron chelator and green tea extract (GTE) as anti-malarial
activity in Plasmodium berghei (P. berghei) infected mice.
Methods: The CM1 (0–100 mg/kg/day) and GTE (0–100 mg (−)-epigallocatechin 3-
gallate equivalent/kg/day) were orally administered to P. berghei infected mice for
consecutive 4 days. Parasitized red blood cells (PRBC) were enumerated by using Gi-
emsa staining microscopic method.
Results: CM1 lowered percentage of PRBC in dose-dependent manner with an ED50
value of 56.91 mg/kg, when compared with pyrimethamine (PYR) (ED50 = 0.76 mg/kg).
GTE treatment did not show any inhibition of the malaria parasite growth. In combined
treatment, CM1 along with 0.6 mg/kg PYR signiﬁcantly inhibited the growth of
P. berghei in mice while GTE did not enhance the PYR anti-malarial activity.
Conclusions: CM1 would be effective per se and synergize with PYR in inhibiting
growth of murine malaria parasites, possibly by limiting iron supply from plasma
transferrin and host PRBC cytoplasm, and chelating catalytic iron cstitutive in parasites’
mitochondrial cytochromes and cytoplasmic ribonucleotide reductase. CM1 would be a
promising adjuvant to enhance PYR anti-malarial activity and minimize the drug
resistance.1. Introduction
Malaria is a virulent infectious diseases associated with
anemia in tropical and subtropical regions, in which Plasmodium
spp. are the causative protozoans [1]. Chemotherapeutic drugs as
chloroquine, pyrimethamine (PYR) and dihydroartemisinin
(DHA) are used for treatment of human malaria infection
based on the actions of b-hematin formation inhibitor, folate
analogue and toxic peroxide metabolites, respectively [2,3].
Though these anti-malarial drugs are widely used to combat
the malaria parasites, increasing drug resistance is a majorproblem in overcoming the pathogen [4]. Essentially,
Plasmodium parasites use iron as a trace element for their
metabolism and fast proliferation [5]. In Plasmodium
falciparum (P. falciparum) infected patients, their serum levels
of iron and transferrin were 19% and 44% respectively
elevated whereas their serum transferrin saturation was 5%
decreased when compared to non-malarial persons, due to
increased synthesis of transferrin by the liver [6]. Meanwhile,
non-transferrin bound iron was detected in plasma of Plasmo-
dium vinckei infected mice [7]. Iron chelators such as
deferoxamine (DFO), deferiprone (DFP) and deferasirox
(DFX) have been reported in suppressing growth of malaria
parasites successfully [8–11]. Some chemicals and medicinal
plants have potential for anti-malarial activity [12–17].
1-(N-Acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-
one (CM1) is a novel orally active bidentate iron chelator with
similar binding afﬁnity constants (log b3 and pFe
III values) toopen access article under the CC BY-NC-ND
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able to remove hepatic ferritin-bound iron and decrease iron
overload effectively in ferrocene-fed b-knock-out thalassemic
mice [19]. IC50 value of the CM1 for growth of P. falciparum in
cultured cells was 35.14 mmol/L when compared with those of
DFO, green tea extract (GTE), DFX and DFP (14.09, 21.11,
44.71 and 58.25 mmol/L, respectively) [20]. Tea (Camellia
sinensis) leaves are enriched with polyphenols, including
(−)-epicatechin, (−)-epicatechin 3-gallate, (−)-epigallocatechin,
(−)-epigallocatechin 3-gallate (EGCG), (+)-catechin and
(−)-gallocatechin [21]. Among them, EGCG, which is the most
abundant catechin, exerts effective antioxidant, iron-chelating
and anti-malarial activity [22–24]. The goals of this study were
to examine CM1 and GTE per se, and their combined
treatments with PYR to inhibit growth of Plasmodium berghei
(P. berghei) in mice.
2. Materials and methods
2.1. Chemicals and reagents
Dimethyl sulfoxide (DMSO) (density 1.10 g/mL) for cell
culture was purchased from Santa Cruz Biotechnology, Inc.
Texas, USA. Standard EGCG (>95% purity) and Giemsa
staining solution were purchased form Sigma–Aldrich Chem-
icals Company, St. Louis, MO, USA. RPMI-1640 (Gibco®
Invitrogen) incomplete medium and phosphate buffered saline
were purchased from Life Technologies, CA, USA. Deionized
water (DI) was locally made by using the Milli®-Q Water Pu-
riﬁcation System, Distillation Equipment (Merck Millipore,
Darmstadt, Germany). Chemicals and reagents are analytical
grade and the highest pure.
2.2. Anti-malarial drugs
PYR and DHA were kindly provided by Dr. Chairat Uthai-
pibull at National Center for Genetic Engineering and Biotech-
nology (BIOTEC), National Science and Technology
Development Agency (NSTDA), Ministry of Science and
Technology, Thailand.
2.3. Iron chelators
DFO (Desferal®, molecular weight = 657) was purchased from
a local drug store atMaharajNakornChiangMaiHospital, Faculty
of Medicine, ChiangMai University, ChiangMai, Thailand. DFP
(GPO-L-One®, molecular weight = 139) and DFX (Exjade®,
molecular weight = 373) were kindly donated by the Research and
Development Institute, Government Pharmaceutical Organiza-
tion, Ministry of Public Health, Bangkok, Thailand. CM1 (mo-
lecular weight = 266, 98% purity) was kindly supplied by Dr.
Kanjana Pangjit, PhD, College of Medicine and Public Health,
Ubol Ratchathani University, Ubol Ratchathani, Thailand [18].
2.4. GTE
A big batch of GTE powder was prepared from fresh tea
leaves according to the method of Srichairatanakool et al. [21].
Antioxidant activity and high EGCG content (24%, w/w) of
the GTE preparation has not been changed for up to 1 year
when it is kept in a plastic bottle in the dark at 4 C.2.5. Animals
Female mice (wild type, C57BL/6 strain), at the age of 4
weeks, with an approximate weight of 25 g, were purchased
from Thalassemia Research Center, Institute of Molecular
Bioscience, Mahidol University Salaya Campus, Bangkok,
Thailand. They were maintained in polyethylene cages in the
Animal House of Medical Faculty, Chiang Mai University under
a controlled condition (12-h day/12-h night light cycle, 25 C
and 40%–70% humidity) and supplied with normal chow pellet
diet and tap water ad libitum. Study protocol was approved by
the Ethical Committee for Animal Experimentation, Faculty of
Medicine, Chiang Mai University, Thailand and followed with
International Guidelines for the Human Use of Animals in
Experimental Studies (Reference Number-42/2556).
2.6. Murine malaria parasites
P. berghei (ANKA strain) infected red blood cells (PRBC)
maintained in a 2 mL cryogenic vial in a liquid nitrogen tank
(−80 C) were thawed by placing in 37 C water bath for 2–
3 min. After that, the mice were injected intraperitoneally (i.p.)
with 0.5 mL of the PRBC. Mouse heart blood was collected in a
lithium heparin tube and diluted the infected blood (1%–10%
parasitemia) in 200 mL of phosphate buffered saline to achieve
1 × 106 PRBC aliquots for further passage of the infection and
experiments [22].
2.7. Drug-susceptibility testing of P. berghei
2.7.1. Single drug treatment
Stock PYR solution was freshly prepared in 100% DMSO.
Stock CM1 and GTE solution were prepared in DI. The doses of
drugs (mg/kg) were adjusted to the weight of mice by diluting
with DMSO (at a ﬁnal concentration of 20%) or DI for every
dose. Blood obtained from P. berghei infected mice (10%–30%
parasitemia) was diluted in RPMI-1640 incomplete medium to
make the blood suspension (1 × 107 PRBC) and injected intra-
peritoneally. The mice (n = 5) were orally administered by
gavage with the tested compounds (PYR 0–5 mg/kg, CM1 0–
100 mg/kg, and GTE 0–100 mg of EGCG equivalent/kg) on Day
0, 1, 2 and 4. Their anti-malarial activity was then evaluated by
using the Peter's 4-day suppressive test [25]. Non-treatment mice
(n = 5) were given an equal volume of 20% DMSO or DI. Tails'
venous blood samples were collected for enumerating parasites
using Giemsa staining microscopic method. Percentage of sup-
pression and parasite growth were calculated using the following
formulae:
% Suppression =
Pn − Pt
Pn
× 100
% Parasite growth =
Pt
Pn
× 100
where Pn is the percentage of parasitemia in non-treatment group
and Pt is the percentage of parasitemia in treatment group.
Maximal 100% parasite growth was normalized from the
mean parasitemia of the non-treatment group and 0% parasite
growth was normalized from the mean parasitemia of the
treatment group with the maximal drug concentration. Dose-
response curve of either suppression or parasite growth, and
ED50 value were made.
Figure 2. Dose-response GTE treatment in P. berghei infected mice.
Data obtained from two independent triplicate experiments were expressed
as mean ± SEM. *P < 0.05; ***P < 0.001 and ****P < 0.0001 when
compared with non-treatment group.
Table 1
Combined treatment of PYR with CM1 in P. berghei infected mice.
Concentration (mg/kg) Parasite growth (%)
0 PYR + 0 CM1 100.0 ± 17.5
0.6 PYR + 0 CM1 23.4 ± 9.0*
0.6 PYR + 12.5 CM1 20.2 ± 5.6
0.6 PYR + 50.0 CM1 12.0 ± 5.7#
0.6 PYR + 100.0 CM1 8.8 ± 3.1#
Data obtained from two independent triplicate experiments were
expressed as mean ± SEM. *: P < 0.05 when compared with non-
treatment group; #: P < 0.05 when compared with 0.6 mg/kg PYR
treatment group.
Table 2
Combined treatment of PYR with GTE in P. berghei infected mice.
Concentration (mg/kg) Parasite growth (%)
0 PYR + 0 GTE 100.0 ± 17.5
0.6 PYR + 0 GTE 23.4 ± 9.0*
0.6 PYR + 12.5 GTE 15.1 ± 2.1
0.6 PYR + 50.0 GTE 19.4 ± 6.3
0.6 PYR + 100.0 GTE 17.6 ± 2.8
Data obtained from two independent triplicate experiments were
expressed as mean ± SEM. *P < 0.05 when compared with non-
treatment group.
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Study procedure of the combined drug treatment was similar
to that of the single drug treatment, in which the PYR concen-
tration was ﬁxed at 0.6 mg/kg, while the CM1 and GTE doses
were varied in the range of 0–100 mg EGCG equivalent/kg.
Blood was collected for enumerating parasites using Giemsa
staining microscopic method. Percentage of suppression and
parasite growth were calculated using the formulae as described
above.
2.8. Statistical analysis
Data were analyzed by using IBM SPSS statistics 20
program software and presented as mean ± SEM. Statistical
signiﬁcance was determined by using student's t-test or
ANOVA test, where P < 0.05 was considered signiﬁcant
different.
3. Results
3.1. Single drug susceptibility test of P. berghei
PYR used as the reference drug clearly showed anti-malarial
activity against P. berghei growth with an ED50 of 0.76 mg/kg
(95% CI = 0.62–0.92 mg/kg). In comparison, CM1 which is our
lead iron-chelating compound also showed anti-malarial activity
against P. berghei growth with an ED50 of 56.91 mg/kg (95%
CI = 47.98–67.50 mg/kg) (Figure 1). Unexpectedly, neither
doses of GTE treatment inhibited P. berghei growth in the
infected mice (Figure 2). The percentage of parasitemia was
increased maximally to 158.41% of the control by GTE treat-
ment (12.5 mg EGCG equivalent/kg) (P < 0.0001). Thereafter,
the parasite growth was declined on the opposite way of
increasing doses of GTE.
3.2. Combined drug susceptibility test of P. berghei
As shown in Table 1, percent P. berghei growth of the PYR
(0.6 mg/kg) treatment group was far lower than that of non-
treatment group (P < 0.05). Most importantly, combined PYR
(0.6 mg/kg) + CM1 (12.5–100 mg/kg) treatment inhibited the
P. berghei growth in mice, depending on the doses of GTE,
which statistical signiﬁcance was found at 50 and 100 mg
EGCG equivalent/kg/day. Combined PYR (0.6 mg/kg) + GTE
(12.5–100 mg/kg) treatment did not enhance efﬁcacy of the PYR
anti-malarial activity when compared with the PYR treatment
alone (Table 2).Figure 1. Dose-response PYR (A) and CM1 (B) treatments in P. berghei infected mice.
Data obtained from two independent triplicate experiments were expressed as mean ± SEM.
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In their growth and development, fast dividing cells like
malaria parasites require large amounts of iron for ribonucleotide
reductase (RR)-catalyzed DNA replication and heme biosyn-
thesis [26–29]. Iron chelators used for treatment of thalassemia-
related iron overload to achieve negative iron balance which
can inhibit parasite growth. Green tea has attractive anti-
inﬂammatory, anti-microbial, cancer chemopreventive, anti-
trypanosomal and anti-plasmodial activities [30–33]. Our
in vitro study showed degree of inhibition of P. falciparum
growth was DFO > GTE > CM1 > DFX > DFP, possibly
due to more lipophilicity of CM1 than DFP and DFX to
penetrate host RBC membrane and parasite plasma membrane
readily [19].
According to leaky membrane of PRBC, we believe that
CM1 would readily penetrate host RBC membrane to remove
intracellular iron in the cytosol and iron-storage protein called
ferritin, leading to iron depletion. Alternatively, CM1 may
speciﬁcally withhold iron from any of several essential iron-
dependent parasite enzymes, involved in CO2 ﬁxation, mito-
chondrial electron transport, pyrimidine synthesis and RR ac-
tivity for DNA synthesis. RR catalyzes the conversion of ribose
to deoxyribose for DNA synthesis and is the most studied target
of iron chelator. In combined treatment, CM1 synergized anti-
malarial activity with PYR to inhibit growth of P. berghei in
mice, consistently with the result of dose–response inhibition of
P. falciparum growth [20]. In this event, PYR will compete with
plasmodial dihydrofolate reductase in the folate-metabolism
pathway and DNA synthesis whereas CM1 chelator may
interact directly on the iron catalytic site on RR molecule.
Alternatively, CM1 would compete with the malaria parasite
siderophore to limit the uptake of extracellular iron and/or
deplete iron stuff persisting in host RBC cytosolic pool and
ferritin [19]. Burte et al. have found that plasma level of hepcidin
was lower in children with cerebral malaria and severe malaria
anemia than in milder anemia children [34]. Recently, we have
found hepcidin gene was upregulated in GTE-fed mice (un-
published data).
Furthermore, GTE was more effective in removing intracel-
lular labile iron pools than CM1 in concentration-dependent
manner, suggesting that a major constituent like EGCG shows
pretty iron-chelating activity besides anti-oxidation [23]. In this
study, we have found that GTE at low doses did not decrease
the percentage of PRBC in P. berghei infected mice; inversely,
they increased. Consistently, Francischetti et al. have reported
that green tea EGCG did not improve survival of P. berghei
infected mice [35]. Interestingly, EGCG, (−)-epicatechin 3-
gallate, caffeoylquinic acid and rosmarinic acid from green tea
potentiated anti-P. falciparum activity of artemisinin but did not
interfere with the folate pathway [36,37]. Digitonin synergistically
increases toxicity of EGCG on survival of plasmodium
sporozoites [38]. It is postulated that GTE would have anti-
hemolytic activity to maintain survival of circulating RBCs, so
the PRBC were not burst to release the persisting merozoites at
the end of erythrocyte stage [39]. Degradation of host RBC
hemoglobin to hemozoin in parasites’ food vacuoles promotes
reactive oxygen species (ROS) generation. The immune system
produced ROS in response to the bursting of PRBC and the
release of merozoites. Taken together, antioxidant GTE has to
diminish ROS production in P. berghei infected mice andconsequently results in promoting rather than inhibiting malaria
parasite growth.
In conclusion, CM1 could inhibit murine malaria parasite
growth and synergize the anti-malarial activity with PYR in
dose-dependent manner. Possible mechanisms included inter-
fering uptake of exogenous iron, depleting cellular iron, and
interacting with functional iron in parasite cells. For effective
treatment and prophylaxis, pharmacokinetics and optimal doses
of CM1 need to be investigated urgently in subjects with malaria
infection.
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